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he collective purchasing organization, OSNN Buyers Club, provides over 
half of all community-based naloxone distributed in the country and is able 
to do so at a 30x lower cost than retail nasal spray. But, dwindling supply of 
the overdose reversal antidote is currently forcing community-based programs to 
heavily ration. Therefore, the Buyers Club has engaged a smaller generic 
manufacturer of injectable 0.4 mg/mL 1mL vials to produce custom batches at 
$2/vial. Timely action is necessary to reserve space on production lines.

The pharmaceutical company is requiring assurance that the naloxone they 
custom manufacture will be purchased. Reassurance in the form of federal 
support is acceptable, but needs national coordination. There is indication that 
non-binding commitments may be acceptable to initiate production.

Pfizer believes supply will be restored in February 2022. Until then, from among 
109 members, we have identified 27 programs that are most vulnerable. They are 
located in 12 states, including the Midwest, Southwest, and Appalachia. Half of 
these programs currently receive no federal funds for naloxone. The programs 
without federal support disproportionately serve historically marginalized 
populations: Native Americans, Latinx, urban African-Americans, and rural 
residents of Appalachia and New England.

The projected shortfall for 2021 is 1 million doses. 





Naloxone Market  
Collectively, naloxone purchased through the Buyers Club accounts for half 
of all community-based distribution in the entire country. 
• OSNN Buyers Club: 1.3 million doses in 2020

• Veterans Administration: 200,000 doses from May 2014 to September 2019 
(source), or 31,000 doses per year.

• Retail Pharmacy: 336,000 doses in 2017 (source) and 556,847 in 2018 (source), 
including intranasal

• Pfizer donation to Direct Relief: 700,000 doses in 2020 (source), zero in 2021

The total naloxone market (all formulations) in the United States is about 5 million 
doses per year, including hospitals. (source) Community-based naloxone 






Federal Support for Naloxone  
53% of Buyers Club programs receive no federal funds for naloxone. 
Internal data from 2020 OSNN Buyers Club survey, n=70 programs responded.

Other Findings 
• Half of Buyers Club programs report having to do fundraising to purchase 
naloxone.

• A quarter of programs (25.3%) report regularly rationing naloxone due to 
inadequate financial support.








Current Naloxone Pricing 
Compared to the nasal sprays, naloxone purchased through the Buyers Club 
is 30x cheaper. 
Intramuscular naloxone is the most cost efficient solution for community-based 
distribution. In the graph below, naloxone costs assume 2.5 doses of 
intramuscular naloxone per kit, and 2 doses for nasal spray. These costs do not 
include distribution labor, packaging, and additional materials. 

In over 2 decades of community-based distribution, the intramuscular naloxone 
formulation among people who use drugs in syringe service programs is 
considered highly acceptable.

During the shortage in 2021, naloxone programs have rapidly depleted budgets 
by purchasing formulations that are substantially more expensive.  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Short-term Supply Restoration 
Short-term: Exclusive Production Run 
A custom production run in October-December would involve registration and 
assignment of a unique NDC number for exclusive use by harm reduction 
programs. The manufacturer would assume costs associated with this 
registration. This arrangement would be included in the OSNN Buyers Club 
catalog and be available to community-based programs in 4Q2021 and beyond. 
The anticipated Product Cost is $2/vial, nearly at-cost to the manufacturer. Final 
costs may be covered under non-disclosure agreements or be subject to 503B 
considerations.

The Real Cost includes additional expenses incurred by community-based 
programs, see Modeling and Assumptions for details. The Real Cost includes: 
educational materials, other equipment (intra-muscular syringes, face shields, 
etc.), packaging, and labor for assembly and distribution.

Reducing reliance on a single manufacturer, once the original Pfizer product 
comes online in 1Q2022, the above solution also provides long-term supply 
chain diversification.  
Batch Increment (doses) Naloxone Product Cost Real Cost
200,000 $400,000 $720,000 to $2,000,000
400,000 $800,000 $1,440,000 to $4,000,000
600,000 $1,200,000 $2,160,000 to $6,000,000
800,000 $1,600,000 $2,880,000 to $8,000,000




We have identified the following threats to long-term viability. We are interested in 
discussing other issues and solutions.

Prescription Requirement 
Smaller programs cannot afford a prescribing physician. Turnover of the 
prescribing physician causes disruptions.

Only a few state standing orders (e.g., Washington) allow purchase of naloxone.

Pfizer imposes additional requirements (DEA registration number) beyond what is 
statutorily necessary.

➡  Consider over-the-counter status for community-based distribution. 
➡  Change state standing orders or provide national standing order. 
Inequitable Distribution 
• Only half of overdose prevention programs receive federal funding.

• Block Grants recipients tend to be more established programs. SSAs often 
show preference for more “establishment” community-based programs, 
systematically disenfranchising programs that serve marginalized populations.

• Outreach to historically marginalized populations is hindered by these structural  
barriers that reinforce inequality.

➡  Centralized purchasing can at least provide product to smaller programs. 
➡  Federal incentives to reach marginalized populations through Block 
Grants. 
Lingering Misinformation 
There is a pervasive belief that intramuscular naloxone is not allowed to be 
purchased using federal funds.

➡  Federal communication to clarify. 
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Most Vulnerable Programs 
Based on OSNN Buyers Club data and conversations with our members, we have 
identified programs have the greatest immediate need for relief, listed in the table 
on the next page. In-State Market Share is the percent of Buyers Club naloxone 
ordered by a program within that state.

Inclusion Criterion: States with programs ordering at least 20,000 doses of 0.4 
mg/mL 1 mL vial injectable naloxone in 2020 through the Pfizer agreement with 
OSNN Buyers Club. Programs make have purchased naloxone elsewhere, in other 
dosage forms, or received donations, which are not reflected herein.

Exclusion Criteria: States with known health department emergency funding or 
arrangements to mitigate current naloxone shortage.

Key Findings 
In 2020, these 27 programs purchased 1.1 million doses. The largest program in 
this list purchased 238,000 doses, and the smallest 400 doses. 

Three programs in AZ, IL, ME purchased more than 100,000 doses each.

Single programs with ~100% market share are effectively the only purchaser for 
the entire state in: Arizona, Kentucky, Louisiana, Maine, Utah, Wisconsin. Loss of 
naloxone access to these programs would be catastrophic.

In Indiana, Illinois, and North Carolina, 2 programs in each state constitute nearly 





The Real Cost includes cost incurred by community-based programs: educational 
materials, other equipment (intra-muscular syringes, face shields, etc.), 
packaging, and labor for assembly and distribution. These costs range from $4 to 
$20/kit depending on packaging selected, local distribution models, and state 
requirements. Real Cost does not factor into account staff time from OSNN 
Buyers Club for onboarding, technical assistance, and paperwork. Real Cost 





• Manufacturing production line batch increment: 200,000 

• Vials per kit: 2 to 3, average for modeling 2.5

• No scale efficiencies or additional costs factored in packaging and distribution

• Manufacturer assumes shipping costs for non-overnight orders

• In-kind donations from manufacturers not represented in estimates above

• Anticipated shortfall for 2021 of 1 million doses is based on 2020 orders placed 
and 2021 backorders

• Community-based programs are willing and able to accept federal funding

• OSNN organizers continue to work volunteer hours

• Costs of mutual aid redistribution are borne by community-based programs

• Paperwork and contracting burdens will be efficient and minimized

• Pfizer (original) naloxone supply will resume at full capacity in February 2022.

Real Cost = product cost + ( doses2.5 doses per kit * $4 to $20 per kit)
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About OSNN Buyers Club 
Established in 2012, OSNN Buyers Club is a collective of US harm reduction 
programs who access low-cost generic injectable naloxone for distribution to 
people who use drugs. The Buyers Club is a project that emerged from the larger 
Opioid Safety and Naloxone Network listserv. The original deal with Pfizer/
Hospira was negotiated by Dan Bigg and Nabarun Dasgupta in 2012. Day-to-day 
management is handled by Maya Doe-Simkins and Eliza Wheeler for the past 




We can be reached at:

	 Dr. Nabarun Dasgupta nab@unc.edu (919) 260-3808

	 Maya Doe-Simkins mdoesimkins@gmail.com

	 Eliza Wheeler ejwharmreduction@gmail.com
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